Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784862 | 0.84 | LMNA (0.44) | PLK1ALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL22955702 | 0.82 | MAPT (0.50) | PLK1ALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL22955708 | 0.80 | LMNA (0.52) | ALDH1A1MAPTL3MBTL1LMNANR4A2 | |
| SCHEMBL22955034 | 0.78 | PLK1 (0.44) | PLK1ALDH1A1MAPTLMNANR4A2 | |
| SCHEMBL8161027 | 0.76 | GPR84 (0.41) | L3MBTL1LMNANR4A2POLBCREBBP | |
| SCHEMBL30373303 | 0.76 | NR4A2 (0.69) | PLK1ALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL2429622 | 0.76 | NR4A2 (0.69) | PLK1ALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL22955995 | 0.75 | MEN1 (0.40) | ALDH1A1MAPTL3MBTL1LMNAPOLB | |
| SCHEMBL22955597 | 0.73 | ALDH1A1 (0.56) | ALDH1A1MAPTL3MBTL1LMNAPOLB | |
| SCHEMBL5065671 | 0.73 | CNR2 (0.68) | PLK1ALDH1A1MAPTCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006014-B1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CN) | 2022-12-20 | — | — | US | disclosed |
| EP-4006014-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | Medshine Discovery Inc. (CN) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021018017-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | 南京明德新药研发有限公司 | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | ERBB2, ERBB3, EGFR | PLK1 134/4885ALDH1A1 3162/4885MAPT 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.